How to Read This Report This report is prepared using the most recent information posted in the FDA's Enforcement Reports Database (for recalls), Warning Letters Database (for warning letters), and Drug Imports Alerts Database (for drug importers subject to import bans)
Cagrilintide is an investigational long-acting amylin analog and is not approved by the FDA, EMA, or any comparable regulator for the treatment, cure, or prevention of obesity, type 2 diabetes, gastrointestinal disorders, or any other condition
E.VaneJ
These medications undergo rigorous FDA oversight, guaranteeing their efficacy and safety, unlike compounded alternatives
Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial